| Rank |
Status |
Study |
| 1 |
Recruiting
|
Antibiotic Treatment of Multiple Erythema Migrans
| Condition: |
Multiple Erythema Migrans |
| Interventions: |
Drug: ceftriaxone; Drug: doxycycline; Other: Erythema migrans patients treated with doxycycline |
| Outcome Measures: |
Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients treated for multiple Erythema migrans with ceftriaxone or doxycycline for 15 days.; Comparison of subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, or irritability between patients treated with antibiotic for multiple Erythema migrans and control subjects without a history of Lyme borreliosis.; Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients with solitary versus multiple Erythema migrans after antibiotic treatment. |
|
| 2 |
Recruiting
|
Cytokines and Chemokines in Erythema Migrans
| Condition: |
Erythema Migrans |
| Intervention: |
Drug: antibiotic treatment |
| Outcome Measures: |
inflammatory proteins in Erythema migrans patients; gene polymorphisms in Erythema migrans patients |
|
| 3 |
Unknown †
|
Affect of Dose Rate on UVR Induced Skin Erythema
| Condition: |
Erythema |
| Intervention: |
Device: exposure to UVB radiation |
| Outcome Measure: |
To examine the difference in Erythemal response as a function of dose rate, and to assess the total amount of energy that is theoretically transmitted through a sunscreen within the range of SPF 2-10 |
|
| 4 |
Recruiting
|
Doxycycline in Therapy of Erythema Migrans
| Condition: |
Lyme Borreliosis |
| Intervention: |
Drug: Doxycycline |
| Outcome Measures: |
Comparing of objective sequelae and post-treatment subjective symptoms in three groups of Erythema migrans patients treated with doxycycline: with no accompanying symptoms, with mild and with severe symptoms at the beginning.; Comparison of subjective symptoms between Erythema migrans patients treated with doxycycline and control subjects without a history of Lyme borreliosis. |
|
| 5 |
Recruiting
|
Analysis of Lyme Disease Lesions
| Conditions: |
Erythema Migrans Lesions; Erythema Migrans |
| Intervention: |
|
| Outcome Measure: |
|
|
| 6 |
Not yet recruiting
|
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema
| Condition: |
Erythema |
| Interventions: |
Drug: CD07805/47 Gel 0.5%; Drug: CD07805/47 Gel Placebo |
| Outcome Measures: |
Composite success on both CEA (Clinician Erythema Assessment ) and PSA (Patient Self Assessment); Composite improvement on both CEA (Clinician Erythema Assessment ) and PSA (Patient Self Assessment) |
|
| 7 |
Not yet recruiting
|
Safety and Efficacy of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea
| Conditions: |
Erythema; Rosacea |
| Interventions: |
Drug: AGN-199201; Drug: Vehicle to AGN-199201 |
| Outcome Measures: |
Percentage of Participants with at Least a 2-Grade Decrease from Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point Scales; Percentage of Participants with at Least a 2-Grade Decrease from Baseline on SSA Using a 5-Point Scale; Change from Baseline in Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA); Satisfaction Assessment for Rosacea Facial Redness Using a 5-Point Scale; Symptom Assessment for Rosacea Facial Redness (Skin Sensation Domain Score) Using a 5-Point Scale; Percentage of Participants with at Least a 1-Grade Decrease from Baseline on SSA Using a 5-Point Scale |
|
| 8 |
Not yet recruiting
|
Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea
| Conditions: |
Erythema; Rosacea |
| Interventions: |
Drug: AGN-199201; Drug: Vehicle to AGN-199201 |
| Outcome Measures: |
Percentage of Participants with at Least a 2-Grade Decrease from Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point Scales; Percentage of Participants with at Least a 2-Grade Decrease from Baseline on SSA Using a 5-Point Scale; Change from Baseline in Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA); Satisfaction Assessment for Rosacea Facial Redness Using a 5-Point Scale; Symptom Assessment for Rosacea Facial Redness (Skin Sensation Domain Score) Using a 5-Point Scale; Percentage of Participants with at Least a 1-Grade Decrease from Baseline on SSA Using a 5-Point Scale |
|
| 9 |
Not yet recruiting
|
A Long-Term Safety and Efficacy Study of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea
| Conditions: |
Erythema; Rosacea |
| Intervention: |
Drug: AGN-199201 |
| Outcome Measures: |
Percentage of Participants with Treatment-Related Adverse Events; Percentage of Participants with at Least a 2-Grade Decrease from Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) Using 5-Point Scales |
|
| 10 |
Recruiting
|
An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema
| Condition: |
Papulopustular Rosacea |
| Interventions: |
Drug: Cromolyn Sodium; Drug: Normal Saline |
| Outcome Measures: |
Facial Erythema; Change in facial Erythema; Matrix Metalloproteinase levels; Change in matrix metalloproteinase levels |
|
| 11 |
Unknown †
|
Pulsed Dye Laser and Intense Pulsed Light (IPL) for the Treatment of Telangiectasia and Skin Redness
| Conditions: |
Telangiectasis; Erythema |
| Interventions: |
Device: Pulsed dye laser; Device: Intense pulsed light |
| Outcome Measure: |
|
|
| 12 |
Recruiting
|
Culture Media for Borrelia Burgdorferi Sensu Lato
| Condition: |
Erythema Migrans |
| Interventions: |
Other: MKP media; Other: BSK-H media |
| Outcome Measure: |
detection of Borrelia burgdorferi sensu lato by microscopy in dark field (positive vs. negative) |
|
| 13 |
Recruiting
|
A Study of Nutritional Supplementation in Altering Ecchymosis, Erythema and Health Outcomes Associated With Aesthetic Procedures
| Condition: |
Ecchymosis and Erythema Commonly Associated With Soft Tissue Filler Injections and Facial Ablative Laser Resurfacing Treatments. |
| Intervention: |
Dietary Supplement: Multizyme Cellular Vitality Cyruta Plus SHEP |
| Outcome Measures: |
Canfield Vectra Photography; Heatherton & Polivy State Self-Esteem (HPSS) Scale, (SkinReplica) at Day 30 as compared to baseline (ablative laser group only, Global Aesthetic Improvement Scale (GAIS, |
|
| 14 |
Unknown †
|
Ciclosporin in the Management of New Erythema Nodosum Leprosum
| Condition: |
Leprosy |
| Interventions: |
Drug: Ciclosporin; Drug: prednisolone |
| Outcome Measures: |
time to relapse of ENL after initial control of symptoms; time, in hours, to control initial episode of ENL relapse from time of starting anti-reactional medication; time, in days, to ENL relapse from date of stopping anti-reactional medication |
|
| 15 |
Unknown †
|
Ciclosporin in the Management of Chronic or Recurrent Erythema Nodosum Leprosum
| Condition: |
Leprosy |
| Interventions: |
Drug: prednisolone; Drug: ciclosporin |
| Outcome Measure: |
|
|
| 16 |
Recruiting
|
Photodynamic Therapy for Papulopustular Rosacea
| Conditions: |
Rosacea; Papulopustular Rosacea |
| Interventions: |
Drug: Aminolevulinic acid topical solution 20%; Device: Blu-U Light Therapy |
| Outcome Measures: |
Improvement of the inflammatory lesions (papules, pustules, nodules), Erythema, and telangiectasia of rosacea as assessed by the Investigator's Global Assessment (IGA); Improvement of the inflammatory lesions (papules, pustules, nodules) of rosacea as assessed by the Inflammatory Lesion Investigator's Global Assessment (ILIGA); Evaluate improvement of rosacea associated Erythema as assessed by the Clinical Erythema Assessment (CEA) scale; Evaluate improvement of the inflammatory lesions (papules, pustules, nodules) of rosacea as measured by a difference in inflammatory lesion count; Evaluate improvement of rosacea as assessed by the Patient Overall Assessment Scale |
|
| 17 |
Unknown †
|
Effect of Additional Clofazimine on Erythema Nodosum Leprosum (ENL) Reactions in Leprosy
| Conditions: |
Borderline Lepromatous Leprosy; Lepromatous Leprosy |
| Interventions: |
Drug: Clofazimine; Drug: Vitamin capsule |
| Outcome Measures: |
Incidence of ENL reactions; Severity of ENL reactions |
|
| 18 |
Unknown †
|
Montelukast in ENL Reaction
| Conditions: |
Erythema Nodosum Leprosum; Leprosy |
| Intervention: |
Drug: montelukast in treatment of ENL reaction |
| Outcome Measures: |
decrease in ENL score; absence of new nerve function impairment; incidence of adverse effects |
|
| 19 |
Recruiting
|
Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
| Conditions: |
Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue; Pyoderma Gangrenosum; Erosive Pustular Dermatosis of the Scalp; Sweet's Syndrome; Behcet's Disease; Bowel-associated Dermatosis-arthritis Syndrome; Pustular Psoriasis; Acute Generalized Exanthematous Pustulosis; Keratoderma Blenorrhagicum; Sneddon-Wilkinson Disease; IgA Pemphigus; Amicrobial Pustulosis of the Folds; Infantile Acropustulosis; Transient Neonatal Pustulosis; Neutrophilic Eccrine Hidradenitis; Rheumatoid Neutrophilic Dermatitis; Neutrophilic Urticaria; Still's Disease; Erythema Marginatum; Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes; Dermatitis Herpetiformis; Linear IgA Bullous Dermatosis; Bullous Systemic Lupus Erythematosus; Inflammatory Epidermolysis Bullosa Aquisita; Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis); Small Vessel Vasculitis Including Urticarial Vasculitis; Erythema Elevatum Diutinum; Medium Vessel Vasculitis |
| Intervention: |
Procedure: Collection of biological samples |
| Outcome Measure: |
Enrichment of rare coding genetic variants |
|
| 20 |
Recruiting
|
Ultherapy® for the Treatment of Erythematotelangiectatic Rosacea
| Conditions: |
Erythematotelangiectatic Rosacea; Rosacea |
| Intervention: |
Device: Ulthera System Treatment |
| Outcome Measures: |
Clinician Erythema Assessment at 90 days post-treatment compared to baseline; CEA scale at 180 days post-treatment compared to baseline.; CEA scale at 365 days post-treatment compared to baseline.; Patient Self-Assessment (PSA) of Erythema at 90 Days compared to baseline.; Patient Self-Assessment (PSA) of Erythema at 180 Days compared to baseline.; Patient Self-Assessment (PSA) of Erythema at 365 Days compared to baseline.; Dermatology Life Quality Index (DLQI) Assessment at 90 Days post-treatment; Dermatology Life Quality Index (DLQI) Assessment at 180 Days post-treatment; Dermatology Life Quality Index (DLQI) Assessment at 365 Days post-treatment; Colorimeter at 90 Days post-treatment; Colorimeter at 180 Days post-treatment; Colorimeter at 365 Days post-treatment |
|
